Czechia· CZ-0286261
PAXLOVID
A nirmatrelvir und ritonavir product containing nirmatrelvir + ritonavir, registered in Czechia by Pfizer Europe MA EEIG, Bruxelles. The same ATC class is registered in 11 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Nirmatrelvir und ritonavir is registered in 11 of 19 countries.
Countries holding a registration under ATC J05AE30 (nirmatrelvir und ritonavir), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 7 of them publish a price we can compare per daily dose
Nirmatrelvir und ritonavir · ATC J05AE30
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of nirmatrelvir und ritonavir costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nirmatrelvir und ritonavir · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$851.25
The record
At a glance
SÚKL (Czech Republic)- Active substance
- NIRMATRELVIR + RITONAVIR
- Manufacturer
- Pfizer Europe MA EEIG, Bruxelles
- Country
- Czechia (CZ)
- ATC code
- J05AE30
- ATC class
- Nirmatrelvir und Ritonavir
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
1 interaction on record for nirmatrelvir und ritonavir.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nirmatrelvir und ritonavir · interactions on record
1 record
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Nirmatrelvir und ritonavir in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayPaxlovidPfizer Europe MA EEIG
- CanadaPAXLOVIDPFIZER CANADA ULC
- FinlandPaxlovidPfizer Europe MA EEIG
- FrancePAXLOVID 150 mg + 100 mg, comprimé pelliculéPFIZER EUROPE MA EEIG (BELGIQUE)
- IcelandPaxlovidPfizer Europe MA EEIG*
- NetherlandsPaxlovid 150 mg filmomhulde tabletten (PF-12345678) en 100 mg filmomhulde tabletten (ritonavir)Pfizer Europe MA EEIG
- PolandPaxlovidPfizer Europe MA EEIG
- SwedenPaxlovid 150 mg + 100 mg Filmdragerad tablettPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Paxlovid
- Liechtenstein · Paxlovid
- Norway · Paxlovid
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/acf75a4b-e375-479d-bd5c-470d0e4b2fde GET /v1/drugs/acf75a4b-e375-479d-bd5c-470d0e4b2fde?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL FLM",
"source": "sukl",
"strength": "150MG+100MG",
"pack_size": "11(6+5)",
"substance": "NIRMATRELVIR + RITONAVIR",
"cz_kod_sukl": "0286261",
"product_type": "CH",
"substance_codes": "1270,14607",
"registration_state": "R",
"registration_number": "EU/1/22/1625/002"
}See everything about nirmatrelvir und ritonavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.